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其中包括 110 例食管癌、20 例平滑肌瘤、18 例上皮内瘤变、14 例食管炎、2 例食
管息肉及 80 例正常对照。此外，我们还收集了 30 份食管癌术前术后配对的血浆标
本；②以 cel-miR-39 为外参，建立可靠稳定的 SYBR Green PCR miR-19a 检测方法，
用于上述血浆中 miR-19a 的相对定量分析；③根据 2-ΔΔCq计算方法，运用 SPSS 统
计软件对上述各个类型疾病中的血浆 miR-19a 表达进行分析，探讨血浆 miR-19a 对
食管癌及食管相关疾病的诊断及预后价值。 




























Background: Esophageal cancer (EC) is a kind of malignant tumor occurred in the 
esophageal epithelium tissue, with a high mortality and high recurrence / metastasis 
rate. However, tumor markers for esophageal cancer is not sensitive enough that they 
can not meet the clinical requirements. MicroRNAs are small regulatory non-coding 
RNAs that are stable and easily detectable in plasma. According to the reports, the 
levels of plasma microRNAs are frequently dysregulated in many diseases stages, 
such as esophageal cancer, colorectal cancer and liver cancer, which greatly increases 
the possibility that plasma microRNAs can be searved as tumor biomakers for 
esophageal cancer. In our previous experiments, we observed that plasma 
microRNA-19a(miR-19a) was up-regulated in esophageal cancer (EC) compared to 
normal healthy controls, so in this paper, we will focus on the clinical values in 
diagnosis and prognosis of miR-19a in esophageal cancer.  
Methods:  ① Plasma samples in 164 patients with esophageal-related diseases (110 
carcinoma, 20 leiomyoma, 18 neoplasia, 14 esophagitis and 2 polyps) and 80 healthy 
controls as well as plasma samples from 30 patients before and after surgical 
treatment were collected; ②Taking cel-miR-39 as external reference, we use SYBR 
Green PCR to establish a raliable method to detect miR-19a;③Combined with clinical 
data, we compared the expression abundence of miR-19a in each type of 
esophageal-related diseases using 2-ΔΔCq method and thus predicted the clinical 















Results: ①We successfully established sensitive and specific detection method for 
miR-19a; ②The concentration of plasma miR-19a was significantly increased in 
patients with EC compared with healthy controls (p<0.001) and its sensitivity in 
esophageal cancer could reach 69.09% and specificity was 77.5%. As for early stages 
of esophageal cancer and esophageal precancerous lesions, the detection rate was 50% 
and 70.83% respectively, which was markedly higher than the current used 
biomarkers. In addition, their specificity could reach 78.75% and 77.5%, respectivity; 
③ The concentration of miR-19a was markedly decreased with the clinical 
improvement of the patients after surgery(p<0.001), moreover, the plasma miR-19a 
level before operation was significantly increased with the recurrence/metastasis of 
patients after surgery(p<0.05); ④ In different types of esophageal cancer, the 
expression of miR-19a in adenocarcinoma was higher than small cell carcinoma and 
aquamous cell carcinoma. 
Conclusion: ①The detection method for miR-19a and cel-miR-39 is sensitive and 
specific; ②The plasma expression of miR-19a in different pathological types of EC 
is significantly different, adenocarcinoma > small cell carcinoma > squamous cell 
carcinoma; ③The plasma miR-19a has promising potential to serve as novel 
effective biomarker for esophageal cancer dignose, prognosis and 
reccurence/metastasis.  

















英文缩写 英文全名 中文名称 
miR microRNA 微小 RNA 
RNA Ribonucleic acid 核糖核酸 
PCR Polymerase Chain Reaction 聚合酶链反应 
Cel-miR-39 C elegens miR-39 线虫 miR-39 
EC Esophageal cancer 食管癌 
Vit Vitamin 维生素 
EGFR Epidermal growth factor 
receptor 
表皮生长因子受体 
CT Compute Tomography X 射线计算机断层摄影 
EUS Endoscopic ultrasonograpy 内镜超声 
PET Positron Emission Tomography 正电子发射计算机断层显像 
CEA Carcino-embryonic antigen 癌胚抗原 
nt Nucleotide 核苷酸 
TNF-α Tumor Necrosis Factor-α 肿瘤坏死因子 α 
UTR Untranslated regions 非翻译区 
OS 
PFS        
Overall survival  
Progress-free survival          
总体生存率 
无进展生存期 
LIS Laboratory information system 实验室信息系统 
AJCC American Joint Committee on 
Cancer 
美国肿瘤研究联合委员会 















dNTP Deoxynucleotide triphosphates 脱氧核苷三磷酸 
OD Optical density 光密度值 
s Second 秒 
min minute 分 
RPM Revolutions per minute 转每分钟 
cDNA complementary DNA 互补脱氧核糖核酸 
Cq Quantitative cycle 循环阈值 
ROC 





SD      
AUC 
CI          
Base pair 
Coefficient of variantion 
Standard deviations 
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第一章  前言 
1.1  食管癌简介 
1.1.1  食管癌发病率 














样导致患者的 5 年生存率不高，仅为 20%~40%左右[4-6]。然而据文献报道，食管















































访有一定的意义[19-21]，Ychou 等人[22] 报道血清 SCC-Ag 的表达与肿瘤体积、病期、
肿瘤浸润深度呈正相关，可以作为食管癌的辅助诊断和判断疾病进程的指标，然
而，在检测食管癌的敏感性方面，SCC-Ag 只有 32.67%[16]。 
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